Next generation multifunctional angiotensin receptor blockers

Hypertension Research

Volumn 32, Issue 10, 2009, Pages 826-834

  Kurtz, Theodore W ^a   Klein, Uwe ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b THERAVANCE INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 [(NITROOXY)METHYL]BENZOATE LOSARTAN; AMLODIPINE PLUS VALSARTAN; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; AZILSARTAN; AZILSARTAN MEDOXOMIL; BMS 248360; BMS 346567; CANDESARTAN; CHLORTALIDONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; ENDOTHELIN RECEPTOR; ENDOTHELIN RECEPTOR ANTAGONIST; GLITAZONE DERIVATIVE; HYDROCHLOROTHIAZIDE; K 868; L 746 072; LCZ 696; MEMBRANE METALLOENDOPEPTIDASE; OMAPATRILAT; PF 03838135; PIOGLITAZONE; PLACEBO; PS 433540; ROSIGLITAZONE; TAK 491; TAK 536; TELMISARTAN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALSARTAN; WB 1106;

ANGIONEUROTIC EDEMA; ANTIHYPERTENSIVE ACTIVITY; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DIABETES MELLITUS; DOSE RESPONSE; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG USE; DRUG WITHDRAWAL; ENZYME ACTIVITY; ENZYME INHIBITION; EXTRAVASATION; GLUCOSE METABOLISM; HEART FAILURE; HEART MUSCLE ISCHEMIA; HUMAN; HYPERTENSION; INSULIN RESISTANCE; KIDNEY INJURY; LOW DRUG DOSE; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PERIPHERAL EDEMA; PROTEINURIA; PULMONARY HYPERTENSION; RECEPTOR BLOCKING; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REPERFUSION INJURY; REVIEW; RISK REDUCTION; SIDE EFFECT; UNSPECIFIED SIDE EFFECT; VASCULAR DISEASE; WEIGHT GAIN;

ANIMALS; ANTIHYPERTENSIVE AGENTS; HUMANS; NEPRILYSIN; NITRIC OXIDE DONORS; PPAR GAMMA; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTORS, ANGIOTENSIN; RECEPTORS, ENDOTHELIN;

EID: 70349980161     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1038/hr.2009.135     Document Type: Review

References (89)

1. Duncia JV, Chiu AT, Carini DJ, Gregory GB, Johnson AL, Price WA, Wells GJ, Wong PC, Calabrese JC, Timmermans PB. The discovery of potent nonpeptide angiotensin II receptor antagonists: A new class of potent antihypertensives. J Med Chem 1990; 33: 1312-1329.
2. Ram CV. Angiotensin receptor blockers: Current status and future prospects. Am J Med 2008; 121: 656-663.
3. McMurray JJ. ACE inhibitors in cardiovascular disease - unbeatable? N Engl J Med 2008; 358: 1615-1616.
4. Matchar DB, McCrory DC, Orlando LA, Patel MR, Patel UD, Patwardhan MB, Powers B, Samsa GP, Gray RN. Systematic review: Comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers for treating essential hypertension. Ann Intern Med 2008; 148: 16-29.
5. Gavras I, Gavras H. Are patients who develop angioedema with ACE inhibition at risk of the same problem with AT1 receptor blockers? Arch Intern Med 2003; 163: 240-241.
6. Haymore BR, Yoon J, Mikita CP, Klote MM, DeZee KJ. Risk of angioedema with angiotensin receptor blockers in patients with prior angioedema associated with angiotensin-converting enzyme inhibitors: A meta-analysis. Ann Allergy Asthma Immunol 2008; 101: 495-499.
7. Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, Dagenais G, Sleight P, Anderson C. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358: 1547-1559.
8. Maillard MP, Wurzner G, Nussberger J, Centeno C, Burnier M, Brunner HR. Comparative angiotensin II receptor blockade in healthy volunteers: The importance of dosing. Clin Pharmacol Ther 2002; 71: 68-76.
9. Oparil S, Silfani TN, Walker JF. Role of angiotensin receptor blockers as monotherapy in reaching blood pressure goals. Am J Hypertens 2005; 18(2 Part 1): 287-294.
10. Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, Toto RD, White A, Cushman WC, White W, Sica D, Ferdinand K, Giles TD, Falkner B, Carey RM. Resistant hypertension: Diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension 2008; 51: 1403-1419.
11. Elliott WJ, Meyer PM. Incident diabetes in clinical trials of antihypertensive drugs: A network meta-analysis. Lancet 2007; 369: 201-207.
12. Gress TW, Nieto FJ, Shahar E, Wofford MR, Brancati FL. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. Atherosclerosis Risk in Communities Study. N Engl J Med 2000; 342: 905-912.
13. Kjeldsen SE, Naditch-Brule L, Perlini S, Zidek W, Farsang C. Increased prevalence of metabolic syndrome in uncontrolled hypertension across Europe: The Global Cardiometabolic Risk Profile in Patients with hypertension disease survey. J Hypertens 2008; 26: 2064-2070.
14. Redon J, Cifkova R, Laurent S, Nilsson P, Narkiewicz K, Erdine S, Mancia G. The metabolic syndrome in hypertension: European society of hypertension position statement. J Hypertens 2008; 26: 1891-1900.
15. Shargorodsky M, Hass E, Boaz M, Gavish D, Zimlichman R. High dose treatment with angiotensin II receptor blocker in patients with hypertension: Differential effect of tissue protection versus blood pressure lowering. Atherosclerosis 2008; 197: 303-310.
16. Hollenberg NK, Parving HH, Viberti G, Remuzzi G, Ritter S, Zelenkofske S, Kandra A, Daley WL, Rocha R. Albuminuria response to very high-dose valsartan in type 2 diabetes mellitus. J Hypertens 2007; 25: 1921-1926.
17. Kaplan NM. Combination therapy for hypertension. Nat Rev Cardiol 2009; 6: 270-271.
18. Morphy R, Rankovic Z. Designed multiple ligands. An emerging drug discovery paradigm. J Med Chem 2005; 48: 6523-6543.
19. Neutel JM. Prescribing patterns in hypertension: The emerging role of fixed-dose combinations for attaining BP goals in hypertensive patients. Current Medical Research and Opinion 2008; 24: 2389-2401.
20. Benson SC, Pershadsingh HA, Ho CI, Chittiboyina A, Desai P, Pravenec M, Qi N, Wang J, Avery MA, Kurtz TW. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPAR{gamma}-modulating activity. Hypertension 2004; 43: 993-1002.
21. Schupp M, Janke J, Clasen R, Unger T, Kintscher U. Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity. Circulation 2004; 109: 2054-2057.
22. Schupp M, Clemenz M, Gineste R, Witt H, Janke J, Helleboid S, Hennuyer N, Ruiz P, Unger T, Staels B, Kintscher U. Molecular characterization of new selective peroxisome proliferator-activated receptor {gamma} modulators with angiotensin receptor blocking activity. Diabetes 2005; 54: 3442-3452.
23. Yusuf S, Teo K, Anderson C, Pogue J, Dyal L, Copland I, Schumacher H, Dagenais G, Sleight P. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: A randomised controlled trial. Lancet 2008; 372: 1174-1183.
24. Yusuf S, Diener HC, Sacco RL, Cotton D, Ounpuu S, Lawton WA, Palesch Y, Martin RH, Albers GW, Bath P, Bornstein N, Chan BP, Chen ST, Cunha L, Dahlof B, De Keyser J, Donnan GA, Estol C, Gorelick P, Gu V, Hermansson K, Hilbrich L, Kaste M, Lu C, Machnig T, Pais P, Roberts R, Skvortsova V, Teal P, Toni D, VanderMaelen C, Voigt T, Weber M, Yoon BW. Telmisartan to prevent recurrent stroke and cardiovascular events. N Engl J Med 2008; 359: 1225-1237.
25. Bosch J, Yusuf S, Gerstein HC, Pogue J, Sheridan P, Dagenais G, Diaz R, Avezum A, Lanas F, Probstfield J, Fodor G, Holman RR. Effect of ramipril on the incidence of diabetes. N Engl J Med 2006; 355: 1551-1562.
26. Dagenais GR, Pogue J, Fox K, Simoons ML, Yusuf S. Angiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: A combined analysis of three trials. Lancet 2006; 368: 581-588.
27. Lithell H, Hansson L, Skoog I, Elmfeldt D, Hofman A, Olofsson B, Trenkwalder P, Zanchetti A. The Study on Cognition and Prognosis in the Elderly (SCOPE): Principal results of a randomized double-blind intervention trial. J Hypertens 2003; 21: 875-886.
28. Tomiyama H, Kushiro T, Abeta H, Ishii T, Takahashi A, Furukawa L, Asagami T, Hino T, Saito F, Otsuka Y. Kinins contribute to the improvement of insulin sensitivity during treatment with angiotensin converting enzyme inhibitor. Hypertension 1994; 23: 450-455.
29. Shiuchi T, Cui TX, Wu L, Nakagami H, Takeda-Matsubara Y, Iwai M, Horiuchi M. ACE inhibitor improves insulin resistance in diabetic mouse via bradykinin and NO. Hypertension 2002; 40: 329-334.
30. Bernobich E, de Angelis L, Lerin C, Bellini G. The role of the angiotensin system in cardiac glucose homeostasis: Therapeutic implications. Drugs 2002; 62: 1295-1314.
31. Scheen AJ. Renin-angiotensin system inhibition prevents type 2 diabetes mellitus. Part 2. Overview of physiological and biochemical mechanisms. Diabetes Metab 2004; 30: 498-505.
32. Goebel M, Clemenz M, Staels B, Unger T, Kintscher U, Gust R. Characterization of new PPARgamma agonists: Analysis of telmisartan's structural components. ChemMedChem 2009; 4: 445-456.
33. Jamerson KA, Nesbitt SD, Amerena JV, Grant E, Julius S. Angiotensin mediates forearm glucose uptake by hemodynamic rather than direct effects. Hypertension 1996; 27: 854-858.
34. Yusuf S, Ostergren JB, Gerstein HC, Pfeffer MA, Swedberg K, Granger CB, Olofsson B, Probstfield J, McMurray JV. Effects of candesartan on the development of a new diagnosis of diabetes mellitus in patients with heart failure. Circulation 2005; 112: 48-53.
35. Takeda Global Research and Development Center. Efficacy and safety of TAK-536 in subjects with essential hypertension. ClinicalTrials.gov Identifier: NCT007595H1. Available at: http://clinicaltrials.gov/ct2/ show/NCT00759551?term=tak-536&rank=1. Accessed June 22, 2009.
36. Takeda Global Research and Development Center. An efficacy and safety study of TAK-491 compared to valsartan and olmesartan in subjects with essential hypertension. ClinicalTrials.gov Identifier: NCT00696436. Available at: http://clinicaltrials.gov/ct2/show/ NCT00696436?term=azilsartan&rank=8. Accessed June 22, 2009.
37. Takeda Pharmaceuticals Press Release. Takeda's investigational compound TAK-536 for treatment of hypertension enters into phase 3 Clinical Trials in Japan. Available at: http://www.takeda.com/press/ article_34500.html. Accessed June 24, 2009.
38. Kohara Y, Kubo K, Imamiya E, Wada T, Inada Y, Naka T. Synthesis and angiotensin II receptor antagonistic activities of benzimidazole derivatives bearing acidic heterocycles as novel tetrazole bioisosteres. J Med Chem 1996; 39: 5228-5235.
39. Iwai M, Chen R, Imura Y, Horiuchi M. TAK-536, a new AT1 receptor blocker, improves glucose intolerance and adipocyte differentiation. Am J Hypertens 2007; 20: 579-586.
40. Takeda Global Research and Development Center. Efficacy and safety of TAK-491 combined with chlorthalidone in subjects with moderate to severe hypertension. ClinicalTrials.gov Identifier: NCT00847626. Available at: http://clinicaltrials.gov/ct2/show/NCT00847626?term=tak-536&rank=4. Accessed June 22, 2009.
41. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Jama 2002; 288: 2981-2997.
42. Black HR, Davis B, Barzilay J, Nwachuku C, Baimbridge C, Marginean H, Wright Jr JT, Basile J, Wong ND, Whelton P, Dart RA, Thadani U. Metabolic and clinical outcomes in nondiabetic individuals with the metabolic syndrome assigned to chlorthalidone, amlodipine, or lisinopril as initial treatment for hypertension: A report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Diabetes Care 2008; 31: 353-360.
43. Hamaguchi Y, Uchii M, Matsubara M, Yanagisawa A, Henmi K, Ueno K, Kusaka H, Yao K. A novel ARB with insulin-sensitizing activity, K-868, prevents diabetic nephropathy in rats. Diabetes 2009; 58(Suppl 1): A208-A209.
44. Pfizer Inc. PF-03838135 non-confidential summary. 2008.
45. Turner AJ. Neprilysin. In: Barrett AJ, Rawlings D, Woessner JF (eds). Handbook of Proteolytic Enzymes. Elsevier: London, 2004, 419-426.
46. Weber MA. Vasopeptidase inhibitors. Lancet 2001; 358: 1525-1532.
47. Kostis JB, Packer M, Black HR, Schmieder R, Henry D, Levy E. Omapatrilat and enalapril in patients with hypertension: The Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) Trial. Am J Hypertens 2004; 17: 103-111.
48. Packer M, Califf RM, Konstam MA, Krum H, McMurray JJ, Rouleau JL, Swedberg K. Comparison of omapatrilat and enalapril in patients with chronic heart failure: The Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE). Circulation 2002; 106 920-926.
49. Rouleau JL, Pfeffer MA, Stewart DJ, Isaac D, Sestier F, Kerut EK, Porter CB, Proulx G, Qian C, Block AJ. Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trial. Lancet 2000; 356: 615-620.
50. Zanchi A, Maillard M, Burnier M. Recent clinical trials with omapatrilat: New developments. Curr Hypertens Rep 2003; 5: 346-352.
51. Fryer RM, Segreti J, Banfor PN, Widomski DL, Backes BJ, Lin CW, Ballaron SJ, Cox BF, Trevillyan JM, Reinhart GA, von Geldern TW. Effect of bradykinin metabolism inhibitors on evoked hypotension in rats: Rank efficacy of enzymes associated with bradykinin-mediated angioedema. Br J Pharmacol 2008; 153: 947-955.
52. Pu Q, Brassard P, Javeshghani DM, Iglarz M, Webb RL, Amiri F, Schiffrin EL. Effects of combined AT1 receptor antagonist/NEP inhibitor on vascular remodeling and cardiac fibrosis in SHRSP. J Hypertens 2008; 26: 322-333.
53. Gardiner SM, March JE, Kemp PA, Ballard SA, Bennett T. Regional hemodynamic effects of neutral endopeptidase inhibition and angiotensin (AT(1)) receptor antagonism alone or in combination in conscious spontaneously hypertensive rats. J Pharmacol Exp Ther 2006; 319 340-348.
54. Hegde LG, Thibodeaux H, Yu C, Cheruvu M, Olsufka R, Renner T, Richardson C, Villarreal J, Armstrong SR, Hegde SS. Comparative preclinical assessment of angioedema risk of inhibitors of renin angiotensin system and neprilysin in the anesthetized rat tracheal plasma extravasation assay. FASEB J 2009; 23 (Abstracts): LB379.
55. Choi SK, Fatheree PR, Hedge S, Hudson R, Jendza K, Marquess D, McKinnell RM, Sasikumar V, Choi SK, Fatheree PR, Hedge S, Hudson R, Jendza K, Marquess D, McKinnell RM, Sasikumar V. Dual-acting antihypertensive agents. US patent application publication, US 2008/0188533.
56. Allegretti P, Choi SK, Gendron R, Fatheree PR, Jendza K, McKinnell RM, McMurtrie C, Olson B. Dual-acting imidazole antihypertensive agents. US patent application publication, US 2009/00232282009.
57. Allegretti P, Choi KS, Fatheree PR, Gendron R, Hudson R, Jendza K, McKinnell RM, McMurtrie C, Olson B. Dual-acting benzoimidazole antihypertensive agents. US patent application publication, US 2008/03189512008.
58. Allegretti PC, Gendron R, Fatheree PR, Jendza K, McKinnell RM, McMurtrie C, Olson B. Dual-acting antihypertensive agents. US patent application publication, US 2008/02693052008.
59. Ksander GM, Webb RL. Methods of treatment and pharmaceutical composition. US patent 7,468,390.
60. Al-Fayoumi S, Hu J, Kumaraperumal N, Royce AE, Ruegger C, Zannou EA. Dual-acting pharmaceutical compositions based on superstructures of angiotensin receptor antagonist/blocker (ARB) and neutral endopeptidase (NEP) inhibitor. PCT International Application Publication 2009, WO 2009/0061713 A1.
61. Feng L, Godtfredsen SE, Karpinski P, Sutton PA, Prashad M, Girgis MJ, Hu B, Liu Y. Pharmaceutical combinations of an angiotensin receptor antagonist and an NEP inhibitor. PCT International Application Publication 2007, WO 2007/056546 A1.
62. Anonymous. Novartis highlights innovative approach to drug discovery with dynamic advance in exploratory pipeline. Pharmaceutical news and articles http://www.drugs.com/news/
63. Dhaun N, Goddard J, Kohan DE, Pollock DM, Schiffrin EL, Webb DJ. Role of endothelin-1 in clinical hypertension: 20 years on. Hypertension 2008; 52: 452-459.
64. Mucke HA. Pulmonary arterial hypertension: On the way to a manageable disease. Curr Opin Investig Drugs 2008; 9: 957-962.
65. Black HR, Bakris GL, Weber MA, Weiss R, Shahawy ME, Marple R, Tannoury G, Linas S, Wiens BL, Linseman JV, Roden R, Gerber MJ. Efficacy and safety of darusentan in patients with resistant hypertension: Results from a randomized, double-blind, placebo-controlled dose-ranging study. J Clin Hypertens (Greenwich) 2007; 9: 760-769.
66. Massart PE, Hodeige DG, Van Mechelen H, Charlier AA, Ketelslegers JM, Heyndrickx GR, Donckier JE. Angiotensin II and endothelin-1 receptor antagonists have cumulative hypotensive effects in canine Page hypertension. J Hypertens 1998; 16: 835-841.
67. Bohlender J, Gerbaulet S, Kramer J, Gross M, Kirchengast M, Dietz R. Synergistic effects of AT(1) and ET(A) receptor blockade in a transgenic, angiotensin II-dependent, rat model. Hypertension 2000; 35: 992-997.
68. Gardiner SM, March JE, Kemp PA, Mullins JJ, Bennett T. Haemodynamic effects of losartan and the endothelin antagonist, SB 209670, in conscious, transgenic ((mRen-2)27), hypertensive rats. Br J Pharmacol 1995; 116: 2237-2244.
69. Ikeda T, Ohta H, Okada M, Kawai N, Nakao R, Siegl PK, Kobayashi T, Miyauchi T, Nishikibe M. Antihypertensive effects of a mixed endothelin-A- and -B-receptor antagonist, J-104132, were augmented in the presence of an AT1 -receptor antagonist, MK-954. J Cardiovasc Pharmacol 2000; 36 (5 Suppl 1): S337-S341.
70. Walsh TF, Fitch KJ, Williams Jr DL, Murphy KL, Nolan NA, Pettibone DJ, Chang RSL, O'Malley SS, Clineschmidt BV, Veber DF, Greenlee WJ. Potent dual antagonists of endothelin and angiotensin II receptors derived from alpha-phenoxyphenylacetic acids (part III). Bioorganic Medicinal Chemistry Letters 1995; 5: 1155-1158.
71. Kowala MC, Murugesan N, Tellew J, Carlson K, Monshizadegan H, Ryan C, Gu Z, Kane B, Fadnis L, Baska RA, Beyer S, Arthur S, Dickinson K, Zhang D, Perrone M, Ferrer P, Giancarli M, Baumann J, Bird E, Panchal B, Yang Y, Trippodo N, Barrish J, Macor JE. Novel dual action AT1 and ETA receptor antagonists reduce blood pressure in experimental hypertension. J Pharmacol Exp Ther 2004; 309: 275-284.
72. Murugesan N, Tellew JE, Gu Z, Kunst BL, Fadnis L, Cornelius LA, Baska RA, Yang Y, Beyer SM, Monshizadegan H, Dickinson KE, Panchal B, Valentine MT, Chong S, Morrison RA, Carlson KE, Powell JR, Moreland S, Barrish JC, Kowala MC, Macor JE. Discovery of N-isoxazolyl biphenylsulfonamides as potent dual angiotensin II and endothelin A receptor antagonists. J Med Chem 2002; 45: 3829-3835.
73. Murugesan N, Gu Z, Fadnis L, Tellew JE, Baska RA, Yang Y, Beyer SM, Monshizadegan H, Dickinson KE, Valentine MT, Humphreys WG, Lan SJ, Ewing WR, Carlson KE, Kowala MC, Zahler R, Macor JE. Dual angiotensin II and endothelin A receptor antagonists: Synthesis of 2′-substituted N-3-isoxazolyl biphenylsulfonamides with improved potency and pharmacokinetics. J Med Chem 2005; 48: 171-179.
74. Floyd DM, Sills MA. Pre-clinical development of PS433540, a dual-acting receptor antagonist (DARA) of the angiotensin and endothelin receptors. J Clin Hypertens 2007; 9 (5, Suppl A): A158.
75. Pollock DM, Derebail VK, Yamamoto T, Pollock JS. Combined effects of AT(1) and ET(A) receptor antagonists, candesartan, and A-127722 in DOCA-salt hypertensive rats. Gen Pharmacol 2000; 34: 337-342.
76. Neutel JM, Graff A, Samson MB, Belder R, Zhang J, Kapil RP. PS433540, a dual angiotensin (AT1) and endothelin (ETA) receptor antagonist (DARA) demonstrates dose-dependent blood pressure lowering effects better than irbesartan in phase IIb dose ranging study in stage1 and stage II hypertensive patients. Presented at the 24th annual meeting of the American Society of Hypertension 2009; http://investors.ligand.com/ releasedetail.cfm?ReleaseID=362687. Accessed June 22, 2009.
77. Stuart-Smith K. Demystified. Nitric oxide. Mol Pathol 2002; 55 360-366.
78. Palmer RM, Ferrige AG, Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 1987; 327: 524-526.
79. Ignarro LJ, Buga GM, Wood KS, Byrns RE, Chaudhuri G. Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide. Proc Natl Acad Sci USA 1987; 84: 9265-9269.
80. Loscalzo J, Welch G. Nitric oxide and its role in the cardiovascular system. Prog Cardiovasc Dis 1995; 38: 87-104.
81. Giles TD. Aspects of nitric oxide in health and disease: A focus on hypertension and cardiovascular disease. J Clin Hypertens (Greenwich) 2006; 8(12 Suppl 4): 2-16.
82. Martelli A, Breschi MC, Calderone V. Pharmacodynamic hybrids coupling established cardiovascular mechanisms of action with additional nitric oxide releasing properties. Curr Pharm Des 2009; 15: 614-636.
83. Karlsson J, Pivodic A, Aguirre D, Schnitzer TJ. Efficacy, safety, and tolerability of the cyclooxygenase-inhibiting nitric oxide donator naproxcinod in treating osteoarthritis of the hip or knee. J Rheumatol 2009; 36: 1290-1297.
84. Breschi MC, Calderone V, Digiacomo M, Macchia M, Martelli A, Martinotti E, Minutolo F, Rapposelli S, Rossello A, Testai L, Balsamo A. New NO-releasing pharmacodynamic hybrids of losartan and its active metabolite: Design, synthesis, and biopharmacological properties. J Med Chem 2006; 49: 2628-2639.
85. Breschi MC, Calderone V, Digiacomo M, Martelli A, Martinotti E, Minutolo F, Rapposelli S, Balsamo A. NO-sartans: A new class of pharmacodynamic hybrids as cardiovascular drugs. J Med Chem 2004; 47: 5597-5600.
86. Li YQ, Ji H, Zhang YH, Shi WB, Meng ZK, Chen XY, Du GT, Tian J. WB1106, a novel nitric oxide-releasing derivative of telmisartan, inhibits hypertension and improves glucose metabolism in rats. Eur J Pharmacol 2007; 577: 100-108.
87. Ali A, Lo MM-C, Franklin C, Almirante N, Stefanini S, Storoni L, Biondi S, Ongini E. Bis(nitrooxy) derivs. as angiotensin II receptor antagonists useful in the treatment of hypertension and their preparation. PCT International Application Publication 2009, WO 2009/070241 A2.
88. Sebhat IK, Lo MM-C, Narugund RP, Ali A, Franklin C, Almirante N, Storoni L, Stefanini S. Preparation of biphenyl compounds containing tetrazole moiety as angiotensin II receptor antagonists. PCT International Application Publication 2008, WO 2008/076246 A2.
89. Sebhat IK, Lo MM-C, Narugund RP, Ali A, Franklin C, Almirante N, Storoni L, Stefanini S. Preparation of losartan dinitrate derivatives and related compounds as angiotensin II receptor antagonists. PCT International Application Publication WO 2008/076247 A2.